Anupam Rasayan India Ltd
Anupam Rasayan India Ltd Q1 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Strong revenue growth expected in FY '26 and beyond, with overall growth of over 30% anticipated. Anupam Rasayan expects strong revenue growth of over 30% in FY '26 driven by all segments: agro, pharma, polymer, and personal care.
From Anupam Rasayan India Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Strong revenue growth expected in FY '26 and beyond, with overall growth of over 30% anticipated.
- Letter of Intents (LOIs) contributing around INR 450-500 crores this year, expected to double compared to last year.
- Similar growth trajectory expected next year as many LOIs and contracts get commercialized and ramped up.
- Pharma segment revenue grew 3x year-on-year, expected to continue strong growth supported by new molecule launches.
- Performance materials segment projected to grow from double-digit contribution to 15-20% in the current year, reaching 20-25% in next 2-3 years.
- Continued strong performance in pharma, polymer, and agrochemical segments.
- Ongoing commercialization of molecules in specialty polymers and fluorochemicals with multinational collaborations expected to support sustained growth.
Profitability & Margins
See what Anupam Rasayan India Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- All planned capex projects have been completed, with plants commissioned and fully operational.
- Two new plants have been commercialized, and trial runs are ongoing in one additional plant.
- No major capex is planned or necessitated in the near term.
- The company is focusing on leveraging existing manufacturing capacities to ramp up new molecule launches and orders.
- Emphasis is on optimizing working capital rather than incurring significant new capital investments in FY '26.
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Anupam Rasayan India Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Current order book stands at INR 14,646 crores, including recently signed LOIs with Japanese and U.S.-based multinational companies.
- LOIs largely cater to polymer (performance chemicals) and agrochemical segments.
- Expected order inflow for the current year is around INR 450-500 crores, with plans to double the LOI contribution compared to last year.
- Similar growth in LOI order book is expected next year as many contracts are commercializing and ramping up.
- Collaboration with a Japan-based fluorochemical conglomerate involves multiple niche molecules, mainly in specialty polymers, with commercialization ramping up next year.
- Order book alignment is strong across pharma, agrochemicals, polymers, and personal care segments, with pharma and polymer segments showing significant growth.
Anupam Rasayan India Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹636 Cr, net profit ₹56 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Anupam Rasayan's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q2 FY26 earnings call →
- Q2 FY26 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
Others in Chemicals & Petrochemicals this season
- Archean Chemical (Q1 FY26)
Q1 FY26 standalone EBITDA grew 13% YoY to INR 958 million with 33% margin; consolidated net profit stood at INR 401 million. Key concall takeaways from Archean…
- PCBL Chemical (Q1 FY26)
Plant closures in Europe/North America may open export opportunities, boosting international sales beyond the current 41% mix. Key concall takeaways from PCBL…
- Rain Industries (Q1 FY26)
Carbon segment capacity utilization is around 68%, with efforts to increase utilization underway. Key concall takeaways from Rain Industries's Q1 FY26 earnings…
- Styrenix Perfor. (Q1 FY26)
Thailand plant utilization is at 50-55% with potential to increase revenue by 70-80% by ramping up capacity and improving product mix. Key concall takeaways…
Frequently Asked Questions
What were Anupam Rasayan India Ltd Q1 FY26 results?
Strong revenue growth expected in FY '26 and beyond, with overall growth of over 30% anticipated. Anupam Rasayan expects strong revenue growth of over 30% in FY '26 driven by all segments: agro, pharma, polymer, and personal care.
What is Anupam Rasayan India Ltd share price analysis?
Anupam Rasayan India Ltd currently shows a neutral. The stock trades at a P/E of 81.4 with a market cap of ₹13,847 Cr. Investors should review the full earnings analysis for detailed insights.
Is Anupam Rasayan India Ltd planning capital expenditure?
All planned capex projects have been completed, with plants commissioned and fully operational.
Keep Anupam Rasayan India Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.